• A cost-effectiveness analysis of the SOPHIA trial data reveals that margetuximab plus chemotherapy is not cost-effective compared to trastuzumab plus chemotherapy for pretreated ERBB2-positive advanced breast cancer patients. • The incremental cost-effectiveness ratio (ICER) for margetuximab was $1,486,442.35/QALY, significantly exceeding the willingness-to-pay threshold. • In a subgroup analysis of CD16A-158F allele carriers, the ICER for margetuximab decreased to $592,669.73/QALY, but remained above acceptable cost-effectiveness levels. • Sensitivity analysis identified the utility of progression-free survival, margetuximab costs, and utility of progressive disease as key factors influencing the cost-effectiveness of margetuximab.

• Gan & Lee Pharmaceuticals' GZR18 injection demonstrated superior HbA1c and body weight reduction compared to semaglutide in T2D patients over 24 weeks. • GZR4 injection showed superior HbA1c reduction versus insulin degludec in T2D patients uncontrolled on basal insulins after 16 weeks. • GZR101 injection exhibited superior efficacy in reducing HbA1c and postprandial glucose compared to insulin degludec/insulin aspart in T2D patients after 16 weeks.

• Final overall survival (OS) results from the phase 3 SOPHIA trial showed margetuximab plus chemotherapy did not significantly improve OS compared to trastuzumab plus chemotherapy in HER2-positive advanced breast cancer. • Median OS was 21.6 months for margetuximab vs. 21.9 months for trastuzumab (HR 0.95; P = .620), with similar OS rates at 12, 18, and 24 months between the two arms. • A subgroup analysis suggested a potential OS benefit with margetuximab in patients carrying the CD16A-158F low-affinity allele, warranting further investigation. • Margetuximab remains a treatment option for pretreated HER2-positive advanced breast cancer, but the study highlights the need for biomarker-driven patient selection.

A phase II trial comparing trastuzumab/pertuzumab with cetuximab/irinotecan in treating RAS/BRAF wild-type HER2-positive metastatic colorectal cancer found no overall difference in progression-free survival. However, patients with higher HER2 gene copy numbers experienced significantly longer progression-free survival with trastuzumab/pertuzumab. The treatment also demonstrated a favorable safety profile, suggesting it as a viable chemotherapy-free option for certain patients.

• Trastuzumab duocarmazine significantly improves progression-free survival compared to physician's choice in pretreated HER2-positive metastatic breast cancer patients. • Combining eribulin with trastuzumab and pertuzumab demonstrates non-inferior progression-free survival versus taxanes in first-line HER2-positive advanced breast cancer. • Pertuzumab retreatment with trastuzumab and chemotherapy shows a significant overall survival benefit in HER2-positive locally advanced/metastatic breast cancer.